Venom immunotherapy: clinical efficacy, safety and contraindications

Košnik, Mitja; Korošec, Peter

doi:10.1586/1744666x.2015.1052409

Cited by 15 publications

(11 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, some promising findings suggested that HBV can be used in combination with standard chemotherapy, e.g., cisplatin 26 , 27 . Another important application of HBV is venom immunotherapy, which is an effective treatment of severe honeybee sting-induced allergic reactions 28 . We have gained knowledge of the mechanism of action of selected HBV compounds 19 , 29 .…”

Section: Introductionmentioning

confidence: 99%

Identification and quantification of honeybee venom constituents by multiplatform metabolomics

Klupczynska

Plewa

Dereziński

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Honeybee (Apis mellifera) venom (HBV) has been a subject of extensive proteomics research; however, scarce information on its metabolite composition can be found in the literature. The aim of the study was to identify and quantify the metabolites present in HBV. To gain the highest metabolite coverage, three different mass spectrometry (MS)-based methodologies were applied. In the first step, untargeted metabolomics was used, which employed high-resolution, accurate-mass Orbitrap MS. It allowed obtaining a broad overview of HBV metabolic components. Then, two targeted metabolomics approaches, which employed triple quadrupole MS, were applied to quantify metabolites in HBV samples. The untargeted metabolomics not only confirmed the presence of amines, amino acids, carbohydrates, and organic acids in HBV, but also provided information on venom components from other metabolite classes (e.g., nucleosides, alcohols, purine and pyrimidine derivatives). The combination of three MS-based metabolomics platforms facilitated the identification of 214 metabolites in HBV samples, among which 138 were quantified. The obtaining of the wide free amino acid profiles of HBV is one of the project’s achievements. Our study contributed significantly to broadening the knowledge about HBV composition and should be continued to obtain the most comprehensive metabolite profile of HBV.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification and quantification of honeybee venom constituents by multiplatform metabolomics

Klupczynska

Plewa

Dereziński

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…VIT is overall effective in protecting at further stings those subjects with HVA, as confirmed by numerous trials , 5 , 9 , 15, 16, 17 where different extract preparations were employed. The occurrence of local (even systemic) reactions still represents one of the main concerns, expecially with Honeybee-VIT.…”

Section: Discussionmentioning

confidence: 71%

Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy

Severino

Simioni²,

Bonadonna

et al. 2019

World Allergy Organization Journal

View full text Add to dashboard Cite

IntroductionIt is acknowledged that any claim of efficacy of allergen immunotherapy must be done for each specific product, and this remains true also for venom immunotherapy (VIT). Thus, we evaluated the efficacy and safety of a specific tyrosine-adsorbed VIT for vespula spp. and honeybee in real-life.MethodsConsecutive patients diagnosed with hymenoptera allergy, and receiving VIT for either vespula or honeybee with a tyrosine-adsorbed preparation were observed to evaluate the grade of reaction (according to Muller) at the first field re-sting. A modified ultra-rush protocol was used.ResultsA total of 247 patients (73 female) were observed (102 honeybee, group H, 145 vespula, group V). Seventy-five patients in group H had a re-sting, and 74/75 had a lower grade reaction at re-sting as compared to the pre-VIT reaction. Considering systemic reactions, protection was achieved in 89% of patients. In group V 118 patients were re-stung, and 76/118 patients with previous grade III-IV reaction had no more systemic reaction under VIT. Overall, considering systemic reactions, protection was achieved in 92% of subjects. Of note, in both groups there was a clear inverse correlation between the severity of pre-VIT and during VIT reactions. The duration of VIT at the time of re-sting did not affect the efficacy. The safety was overall good, with 18% ad 15.4% local reactions in groups H and V, respectively.DiscussionModified extracts, including tyrosine-absorbed, have the aim of improving the safety of VIT still yet maintaining the efficacy. Field re-sting is the best way to assess the efficacy in real life. In this observational study we could confirm the protective efficacy of the tyrosine-adsorbed extract, with a good safety expecially in the build-up using a modified-rush protocol.ConclusionThe tyrosine-adsorbed VIT used herein is a viable and advantageous form of treatment for hymenoptera allergy.

show abstract

“…Potrzeba użycia adrenaliny z powodu NDS może dotyczyć 0,2-5,0% chorych poddawanych VIT [23]. Do istotnych czynników zwiększających ryzyko wystąpienia NDS w trakcie VIT należą: faza dawek wzrastających i rodzaj użytego schematu, starszy wiek (głównie z powodu chorób sercowo-naczyniowych), mastocytoza lub duże wyjściowe stężenie tryptazy [23][24][25][26]. Dlatego też przed VIT z jadem pszczoły zaleca się ocenę aktywacji bazofilów na alergen (BAT, odsetek bazofilów CD 63+) w celu identyfikacji chorego z dużym ryzykiem rozwoju ciężkich NDS [25].…”

Section: Bezpieczeństwo Immunoterapii Alergenowej W Alergii Na Jad Owunclassified